- Treatment should be an essential component of a tobacco control strategy and should be integrated with other tobacco control policies; for example, taxation increases should be combined with greater availability of treatment (see also Treatment Guidelines section of the Efficacy section).
- Treatment should be accessible to all tobacco users, including those whose tobacco use is primarily explained by self-medication. This would include those who are dependent upon tobacco products as a way of dealing with the conditions for which tobacco/nicotine appears to alleviate symptoms (schizophrenia, ADHD, chronic depression etc.).
- Treatment systems should as far as possible offer, and make accessible to all tobacco users, a full range of effective treatments, such as routine advice to stop by healthcare professionals, more intensive support to quit (given individually or in groups), and pharmacological approaches.
- Effective treatment interventions should be integrated into, and funded from within, healthcare systems.
- Pre- and post-certification education and training in cessation of tobacco use should be introduced into the curricula of healthcare professionals.
- Treatment systems should offer a range of indicated uses for treatment products, consistent with the evidence on efficacy, scientific understanding of the nature and causes of tobacco use and relapse, and the needs of consumers to choose the interventions most acceptable to them.
- The regulatory barriers that prevent effective treatment products being made as widely available as possible should be reformed so that at the very least, addicted tobacco users who wish to stop can acquire tobacco dependence treatment products at least as easily as they can acquire tobacco products.
- Campaigns should continue to be developed to increase public awareness of the benefits of quitting and the treatment options available.
|
